All In Biotech

Drug Trial Radar · NCT04302870

Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,150

Planned (sponsor's estimate)

Start

Feb 27, 2020

Primary completion

Dec 2030

Study completion Dec 2030

Sponsor

Lead sponsor
University of EdinburghAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University College, London; University of Warwick; NHS Lothian
First posted
Mar 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MND-SMART is investigating whether selected drugs can slow down the progression of motor neuron disease (MND) and improve survival. The study is 'multi-arm' meaning more than one treatment will be tested at the same time. The trial started with 3 arms; drug 1 (memantine), drug 2 (trazodone) and placebo (dummy drug). A third drug, amantadine, was added in April 2023. A fourth drug, tacrolimus, was added in March 2025 in Edinburgh and across all sites in April 2025. The first two drugs, memantine and trazodone, were removed from the trial in September 2023 due to lack of benefit. The trial currently has 4 recruiting arms; amantadine, liquid placebo (matched to amantadine), tacrolimus, and tablet placebo (matched to tacrolimus). This allows the evaluation of each drug versus placebo. Participants will be randomly allocated between the treatment arms they are eligible for. Medicines being tested are already approved for use in other conditions. MND-SMART has an 'adaptive' design. This means medicines being studied can change according to emerging results. Treatments shown to be ineffective can be dropped and new drugs can be added over the duration of the study. This will allow many treatments, over time, to be efficiently and definitively evaluated. The medicines being tested have been selected following a rigorous process involving a systematic, unbiased, and comprehensive review of past clinical trials data, as well as information from pre-clinical research (studies in laboratories), for MND and other related neurodegenerative disorders. Drugs have been ranked for inclusion in MND-SMART by a group of independent MND experts according to set criteria. These include consideration of how the drugs work, their safety profiles, and the quality of previous studies. New drugs will be selected for investigation in MND-SMART based on continuous review of constantly updated scientific evidence as well as findings from state-of-the-art human stem cell based drug discovery platforms. These can be added by substantial amendment to the protocol.

Conditions

  • Motor Neuron Disease, Amyotrophic Lateral Sclerosis

Interventions

  • Memantine Hydrochloride Oral SolutionDrug

    Memantine hydrocholoride taken once daily

  • Trazodone Hydrochloride oral solutionDrug

    Trazodone Hydrochloride taken once daily

  • Placebo oral solutionDrug

    Placebo taken once daily

  • Amantadine Hydrochloride Oral SolutionDrug

    Amantadine Hydrochloride taken once daily

  • Tacrolimus 1Mg CapDrug

    Tacrolimus 1Mg overencapsulated tablet taken once daily

  • Placebo capsuleDrug

    Placebo taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in decline of ALS-FRS(R) over 18monthsTime frame: 18 months
  2. SurvivalTime frame: 18 months

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom · Recruiting

  • University Hospitals of Birmingham NHS Foundation Trust

    Birmingham, United Kingdom · Recruiting

  • University Hospitals Sussex NHS Foundation Trust

    Brighton, United Kingdom · Recruiting

  • West Suffolk NHS Foundation Trust

    Bury St Edmunds, United Kingdom · Recruiting

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom · Recruiting

  • Cardiff and Vale University Local Health Board

    Cardiff, United Kingdom · Recruiting

  • Clinical Research Centre , Ninewells Hospital

    Dundee, United Kingdom · Recruiting

  • Anne Rowling Regenerative Neurology Clinic

    Edinburgh, United Kingdom · Recruiting

  • Royal Devon and Exeter Hospital

    Exeter, United Kingdom · Recruiting

  • Queen Elizabeth University Hospital Clinical Research Facility

    Glasgow, United Kingdom · Recruiting

  • NHS Highland Clinical Research Facility, Raigmore Hospital

    Inverness, United Kingdom · Recruiting

  • East Suffolk and North Essex NHS Foundation Trust

    Ipswich, United Kingdom · Recruiting

  • Royal London Hospital

    London, United Kingdom · Recruiting

  • St George's University Hospitals NHS Foundation Trust

    London, United Kingdom · Recruiting

  • King's College Hospital NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Norfolk and Norwich University Hospitals NHS Foundation Trust

    Norwich, United Kingdom · Recruiting

  • University Hospitals of Dorset NHS Trust

    Poole, United Kingdom · Recruiting

  • Clinical Research Facility Salford Royal NHS Foundation Trust

    Salford, United Kingdom · Recruiting

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, United Kingdom · Recruiting

  • Clinical Research Facility University Hospital Southampton

    Southampton, United Kingdom · Recruiting

  • Southern Health and Social Care Trust, Craigavon Area Hospital

    Portadown, County Armagh, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.